



Marie Yeager
Cancer Center

2023

Cancer Care Report

Data collected in 2022 and reported in 2023

Each year we look at cancer cases locally and nationally in order to understand trends, support cancer research, measure progress in prevention efforts, and to improve cancer outcomes.

As an accredited organization we have proven ourselves through legitimate third parties that we meet or exceed strict quality standards.

- Accredited with commendation by the Commission on Cancer (CoC) of the American College of Surgeons (ACoS) as a Community Hospital Comprehensive Cancer Program.
- The Radiation Oncology Department is accredited by the American College of Radiology (ACR).
- Fully accredited by the National Accreditation Program for Breast Centers (NAPBC), a program administered by the American College of Surgeons.
- Member of the American Society of Clinical Oncology (ASCO).
- Member of the American Society for Radiation Oncology (ASTRO).
- Gold seal of approval from The Joint Commission.
- Participates in the Michigan Radiation Oncology Quality Consortium and the Cancer Research Consortium of West Michigan.

Read on to learn more about cancer cases from 2022 in Michigan, the United States, and at Corewell Health Lakeland Hospitals specifically.



spectrumhealthlakeland.org/cancer-care

Statistical summary and review of registry data 2022

In 2022, 1,339 cases were added to the Corewell Health in Southwest Michigan Cancer Registry. Of these cases, 1,206 cases were considered analytic, which means that they received all or part of their first course treatment locally, or were diagnosed by Corewell Health in Southwest Michigan and received all first course treatment elsewhere. The number of cisgender males were **601 (44.89%)**, cisgender female were **736 (54.97%)**, transgender female was **one (0.7%)**, and transgender male was **one (0.7%)**.

Patients diagnosed at age 60 years or older accounted for 72.97% of cases. Patients 30 through 59 years of age accounted for 25.16%, while 1.87% of cases were 29 years old or younger. The mean age of cancer patients in 2022 was 65.

Non-analytic cases are those that were diagnosed and received all first course treatment elsewhere, and came to Corewell Health for subsequent treatment for either recurrence or persistence of their disease.

Figure 1a
2022 ratio of female to male patients




Figure 1b
2022 age distribution




Figure 2
Percent distribution of Corewell Health Lakeland Hospitals' 2022 cancer cases by age decade




Table 1

Site distribution by stage for the four most common cancer sites at Corewell Health Lakeland Hospitals*

	Cases	Stage 0	Stage I	Stage II	Stage III	Stage IV	UNK Staged
Breast	185	29	108	27	12	7	2
Lung	181	0	52	13	29	85	2
Prostate	134	0	31	45	26	20	12
Colorectal	109	8	20	19	29	29	4

Table 2

Comparison of four most common cancer sites, Corewell Health Lakeland Hospitals, state of Michigan, and United States

Corewell Health Lakeland Hospitals				Michigan		United States	
Site	Rank	Cases	% of Total	Rank	% of Total	Rank	% of Total
Breast	1	185	13.81%	2	14.28%	1	15.00%
Lung	2	181	13.51%	3	13.95%	3	12.34%
Prostate	3	134	10.00%	1	14.78%	2	13.99%
Colon/rectum	4	109	8.14%	4	7.48%	4	7.87%

*American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022, pg 4-5.

Table 3


Comparison of percent distribution of Corewell Health Lakeland Hospitals 2022 cancer cases and United States data by gender and four most common cancer sites

Site	Male Cancer Cases		Female Cancer Cases	
	United States*	Lakeland	United States*	Lakeland
Breast	0.27%	0.33%	30.79%	24.86%
Prostate	27.30%	22.29%	NA	NA
Lung	11.99%	14.47%	12.71%	12.77%
Colorectal	8.20%	8.48%	7.52%	7.88%

*American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022 pg 4.

Figure 3

Comparison of percent distributions of Corewell Health Lakeland Hospitals three most common female and male cancer sites for 2022 and United States data*

**Figure 4**

Comparison of percent distribution of Corewell Health Lakeland Hospitals' 2022 cancer cases by gender





Figure 5a

Distribution of Corewell Health Lakeland Hospitals cancer cases by county

**Figure 5b**

Distribution of Corewell Health Lakeland Hospitals cancer cases by city (Berrien, Cass, Van Buren counties)





Figure 6

Distribution of total cancer cases by primary site



*CIN III (non-invasive cervical severe dysplasia) is accessioned by agreement, but for 2022 the collection of this data was mandated by the State of Michigan

Table 4

Summary: By body, system, and gender

Primary Site	Total	Percent	Male	Percent	Female	Percent
BRAIN & OTHER NERVOUS SYSTEM	118	8.8%	42	6.8%	76	10.3%
Brain	19	1.4%	12	2.0%	7	0.9%
Cranial Nerves other Nervous System	99	7.4%	30	4.8%	69	9.4%
BONES & JOINTS	1	0.1%	0	0.0%	1	0.1%
BREAST	185	13.8%	2	0.3%	183	24.8%
DIGESTIVE SYSTEM	218	16.3%	121	20.1%	97	13.2%
Anus, Anal Canal & Anorectum	8	0.6%	3	0.5%	5	0.7%
Colon Excluding Rectum	76	5.7%	31	5.2%	45	6.1%
Esophagus	21	1.6%	20	3.3%	1	0.1%
Gallbladder	3	0.2%	0	0.0%	3	0.4%
Liver & Intrahepatic Bile Duct	17	1.3%	9	1.5%	8	1.1%
Rectum & Rectosigmoid	33	2.5%	20	3.3%	13	1.8%
Small Intestine	10	0.7%	5	0.8%	5	0.7%
Stomach	12	0.9%	11	1.8%	1	0.1%
Other Biliary	3	0.2%	1	0.2%	2	0.3%
Pancreas	34	2.5%	21	3.5%	13	1.8%
Peritoneum, Omentum & Mesenteric	1	0.1%	0	0.0%	1	0.1%
ENDOCRINE SYSTEM	44	3.3%	14	2.3%	30	4.1%
Thyroid	12	0.9%	4	0.7%	8	1.1%
Other Endocrine including Thymus	32	2.4%	10	1.7%	22	3.0%
EYE & ORBIT	1	0.1%	0	0.0%	1	0.1%
FEMALE GENITAL SYSTEM	142	10.6%	0	0.0%	142	19.1%
Cervix Uteri	78	5.8%	0	0.0%	78	10.4%
Corpus & Uterus, NOS	48	3.6%	0	0.0%	48	6.6%
Ovary	8	0.6%	0	0.0%	8	1.1%
Vagina	1	0.1%	0	0.0%	1	0.1%
Vulva	6	0.4%	0	0.0%	6	0.8%
Other Female Genital Organs	1	0.1%	0	0.0%	1	0.1%
LEUKEMIA	35	2.7%	18	3.0%	17	2.4%
Lymphocytic Leukemia	19	1.5%	9	1.5%	10	1.5%
Myeloid & Monocytic Leukemia	15	1.1%	8	1.3%	7	0.9%
Other Leukemia	1	0.1%	1	0.2%	0	0.0%

Table 4 (continued)
Summary: By body, system, and gender

Primary Site	Total	Percent	Male	Percent	Female	Percent
LYMPHOMA	31	2.3%	18	3.0%	13	1.8%
Hodgkins Lymphoma	3	0.2%	2	0.3%	1	0.1%
Non-Hodgkin Lymphoma	28	2.1%	16	2.7%	12	1.6%
MALE GENITAL SYSTEM	141	10.5%	141	23.5%	0	0.0%
Prostate	134	10.0%	134	22.3%	0	0.0%
Testis	7	0.5%	7	1.2%	0	0.0%
MESOTHELIOMA	2	0.1%	2	0.3%	0	0.0%
MYELOMA	24	1.8%	15	2.5%	9	1.2%
ORAL CAVITY & PHARYNX	26	1.9%	20	3.3%	6	0.8%
Tongue	13	1.0%	12	2.0%	1	0.1%
Salivary Glands	2	0.1%	1	0.2%	1	0.1%
Floor of Mouth	1	0.1%	1	0.2%	0	0.0%
Gum & Other Mouth	2	0.1%	1	0.2%	1	0.1%
Nasopharynx	1	0.1%	1	0.2%	0	0.0%
Tonsil	7	0.5%	4	0.7%	3	0.4%
RESPIRATORY SYSTEM	198	14.8%	100	16.6%	98	13.3%
Larynx	16	1.2%	13	2.2%	3	0.4%
Lung & Bronchus	181	13.5%	87	14.5%	94	12.8%
Trachea, Mediastinum and Other Respiratory Organs	1	0.1%	0	0.0%	1	0.1%
SKIN EXCLUDING BASAL & SQUAMOUS	45	3.3%	24	4.0%	21	2.8%
Melanoma - Skin	42	3.1%	22	3.7%	20	2.7%
Other Non=Epithelial Skin	3	0.2%	2	0.3%	1	0.1%
SOFT TISSUE (including heart)	1	0.1%	0	0.0%	1	0.1%
URINARY SYSTEM	95	7.1%	70	11.6%	25	3.4%
Kidney & Renal Pelvis	44	3.3%	29	4.8%	15	2.0%
Urinary Bladder	46	3.4%	38	6.3%	8	1.1%
Ureter	5	0.4%	3	0.5%	2	0.3%
MISCELLANEOUS	31	2.3%	14	2.3%	17	2.3%
Acute Myeloid Leukemia w/ Mutated RUNX1	1	0.1%	1	.2%	1	0.0%
Total	1,339		602		737	